Congratulations to Nicolas who won the poster prize (2nd place) at the 20th Annual Research Presentations hold by the University of Bergen at Sentralblokka, Haukeland University Hospital, 28–30 January 2026. Poster: Myeloid-Specific Immunomodulatory Profiles Predict Relapse in Patients With Non-metastatic Proximal Colon Cancer. Nicolas Mattias Del Rio Fuenzalida, Kristin Bentung Lygre, Rakel Brendsdal Forthun, Reidun Kristin Kopperud, Pål Tore READ MORE

Luiza Ghila and her team in Cell Fate Lab has been awarded funding from The Norwegian Cancer Society’s call “Researcher projects 2025” for the research project “Mapping the bladder tumour immune microenvironment by single cell technologies“. More information is found here: https://chera.w.uib.no/2025/12/grant-award-the-norwegian-cancer-society/

The Trond Mohn Foundation has newly awarded 18 millions NOK to three cancer research projects, one of which is HUVAMER-project “HUVAMER – Home Treatment for Blood Cancer” led by Professor Dr. med. Bjørn Tore Gjertsen. The HUVAMER-project is aimed to test two repurposed drug combinations (hydroxyurea + valproate, and 6-mercaptopurine + valproate) in treatment of READ MORE

On September 10-12th 2025, the Nordic AML Group Meeting took its place in Bergen – Norway. The meeting was organised by the Nordic AML Group (https://www.namlg.org/) chaired by Professor Dr. med. Bjørn Tore Gjertsen. The K.G. Jebsen-Centre for Myeloid Blood Cancer (CMYC) contributed as the local organising committee, the technical organizer for the meeting, and READ MORE